Valganciclovir hydrochloride for Oral (Actavis Pharma, Inc.)
Welcome to the PulseAid listing for the Valganciclovir hydrochloride for Oral drug offered from Actavis Pharma, Inc.. This Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC],DNA Polymerase Inhibitors [MoA],Nucleoside Analog [Chemical/Ingredient],Nucleoside Analog Antiviral [EPC] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Actavis Pharma, Inc. |
| NON-PROPRIETARY NAME: | Valganciclovir hydrochloride |
| SUBSTANCE NAME: | VALGANCICLOVIR HYDROCHLORIDE |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC],DNA Polymerase Inhibitors [MoA],Nucleoside Analog [Chemical/Ingredient],Nucleoside Analog Antiviral [EPC] |
| ROUTE: | ORAL |
| DOSAGE FORM: | POWDER, FOR SOLUTION |
| MARKETING CATEGORY NAME: | ANDA |
| START MARKETING DATE: | 2016-08-26 |
| END MARKETING DATE: | 0000-00-00 |
Valganciclovir hydrochloride for Oral HUMAN PRESCRIPTION DRUG Details:
| Item Description | Valganciclovir hydrochloride for Oral from Actavis Pharma, Inc. |
| LABELER NAME: | Actavis Pharma, Inc. |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 50(mg/mL) |
| START MARKETING DATE: | 2016-08-26 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 0591-2579_4db4ac19-5bfd-4713-a385-0ef86eb4b632 |
| PRODUCT NDC: | 0591-2579 |
| APPLICATION NUMBER: | ANDA205220 |
Other VALGANCICLOVIR HYDROCHLORIDE Pharmaceutical Manufacturers / Labelers:
